Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Reflections on adjuvant treatment of gastric cancer

Authors Albert Abad, José Luis Manzano, Cristina Martí

Published 15 September 2007 Volume 2007:3(4) Pages 563—567

Albert Abad, José Luis Manzano, Cristina Martí

Servicio de Oncología Médica (Medical Oncology Service), Hospital Universitari Germans Trias i Pujol, Institut Català d’Oncologia (ICO) Badalona, Barcelona, Spain

Abstract: Gastric cancer constitutes a significant health problem in the world due to its high incidence in certain geographical areas. The basic treatment of this tumor in its localized stages is surgery. Unfortunately, survival is less than 5 years, despite radical surgery. Radical and extensive surgery has proved to be crucial to survival, although there is no agreement on the need for reaching the nodes until there is more than 3 cm of tumor. However, even with the most extensive surgery, survival does not reach more than approximately 35% at 5 years, if we consider all the localized stages. Adjuvant treatment is therefore necessary for this neoplasm. The role of post-operative chemotherapy, as that of radiochemotherapy, is not well established and there is no standard. However, there is relative evidence of the benefit of adjuvant treatment in some chemotherapy studies and in combination with radiotherapy, so that it is an option for treatment in these patients.

Keywords: gastric cancer, adjuvant, chemotherapy, radiotherapy

Download Article [PDF] 

Readers of this article also read:

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Treatment strategies in mucous membrane pemphigoid

Ann G Neff, Matthew Turner, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:617-626

Published Date: 6 June 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment

Sigliti-Henrietta Pelidou, Sotirios Giannopoulos, Sotiria Tzavidi, Georgios Lagos, Athanassios P Kyritsis

Therapeutics and Clinical Risk Management 2008, 4:627-630

Published Date: 6 June 2008

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007